![]() Graphite Bio Graphite Bio is a gene-editing company focused on the development of therapies for patients suffering from life-threatening genetic diseases. | ProQR Therapeutics ProQR Therapeutics is a company that develops RNA therapies designed for patients suffering from genetic rare diseases. | Precigen Precigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases. | |
Founding Date | Founding Date 2017 | Founding Date 2012 | Founding Date 1998 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations South San Francisco, US HQ | Locations Leiden, NL HQ Cambridge, US | Locations Germantown, US HQ Gent, BE Sioux Center, US |
Employees | Employees 27 | Employees 166 | Employees 601 |
Valuation ($) | Valuation ($) 185.2 m | Valuation ($) 281.8 m | Valuation ($) 246.6 m |
Financial | |||
Revenue (est.) | Revenue (est.) $19.1m (FY, 2025) | Revenue (est.) €15.9m (FY, 2025) | Revenue (est.) $9.7m (FY, 2025) |
Cost of goods | Cost of goods $418k (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $18.7m (FY, 2025) | Gross profit €16.3m (FY, 2025) | Gross profit N/A |
Net income | Net income ($82.1m) (FY, 2025) | Net income (€42.2m) (FY, 2025) | Net income ($250.6m) (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised N/A | Total funding raised $ 57.8m | Total funding raised $ 379m |
ProQR Therapeutics is a company that develops RNA therapies designed for patients suffering from genetic rare diseases.
View companyPrecigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases.
View company